were divided in two groups based on additional treatment to ongoing therapy:
the empagliflozin and incretin groups. Nondiabetic healthy subjects were
defined as the control group. Based on the time to peak dilation at the FMD
test, subjects in the empagliflozin and incretin groups were divided into
three different categories: early, late and no dilators. The incretin group
was further divided into those who were administered sitagliptin or
liraglutide to evaluate drug-related differences. Triglycerides, blood
viscosity and SS were not normally distributed; therefore, they were
log-transformed before statistical analyses. Continuous variables were
compared using the t-test for paired and unpaired tests
where applicable. The chi-square test was used to compare percentages
between groups. Analysis of variance (ANOVA) and Bonferroni post hoc tests
as well as the general linear model for repeated measures were used to
evaluate differences among subjects divided in three groups.